Anti-IL-6 monoclonal antibody pacibekitug sustains inflammation reduction through six months in kidney disease patients
Source Summary
The investigational monoclonal antibody pacibekitug, which targets interleukin-6, demonstrated sustained reductions in inflammation-related biomarkers over a six-month period. The treatment was studied in patients with chronic kidney disease who had elevated inflammatory risk associated with heart disease.
Why it matters
Sustained reduction of inflammation biomarkers in chronic kidney disease patients with cardiac risk may indicate a potential therapeutic approach to reduce cardiovascular complications in this high-risk population.
